SCHEMBL23577378

SCHEMBL23577378

O=C(c1ccc(C2(OCCO)COC2)cc1)N1CCC(c2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ CNR1 P21554 1/20 0.43
▸ HSD11B1 P28845 1/20 0.43
▸ EGLN1 Q9GZT9 1/20 0.43
▸ MGLL Q99685 1/20 0.42
▸ EPHX2 P34913 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ MAPK7 Q13164 1/20 0.42
▸ TEAD1 P28347 1/20 0.41
▸ FASN P49327 3/20 0.41
▸ PARP10 Q53GL7 1/20 0.40
▸ SLC9A1 P19634 1/20 0.40
▸ JAK2 O60674 1/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.39
▸ MRGPRX4 Q96LA9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23577508 0.90 GAA (0.46) GAATDP1CNR1HSD11B1EGLN1
SCHEMBL23577764 0.89 GAA (0.45) GAATDP1CNR1HSD11B1EGLN1
SCHEMBL23577488 0.89 EGLN1 (0.47) GAATDP1CNR1HSD11B1EGLN1
SCHEMBL23577850 0.88 CNR1 (0.44) GAATDP1CNR1HSD11B1EGLN1
SCHEMBL23577778 0.88 GAA (0.41) GAATDP1CNR1HSD11B1EGLN1
SCHEMBL23577479 0.87 GAA (0.43) GAATDP1CNR1HSD11B1EGLN1
SCHEMBL23577904 0.87 GAA (0.46) GAATDP1CNR1HSD11B1EGLN1
SCHEMBL23577339 0.86 MAPK7 (0.48) GAATDP1CNR1HSD11B1EGLN1
SCHEMBL23577492 0.85 EGLN1 (0.42) GAATDP1CNR1HSD11B1EGLN1
SCHEMBL28818495 0.85 GAA (0.47) GAATDP1CNR1HSD11B1EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081509-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA Zydus Lifesciences Limited (IN) 2022-11-02 — — EP claimed
WO-2021130723-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LIMITED (IN) 2021-07-01 — — WO claimed
US-20230089247-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA ZYDUS LIFESCIENCES LIMITED (IN) 2023-03-23 — — US disclosed
EP-4081509-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA Zydus Lifesciences Limited (IN) 2022-11-02 — — EP disclosed
WO-2021130723-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LIMITED (IN) 2021-07-01 — — WO disclosed
WO-2021130723-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LIMITED (IN) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089247-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA PCSK9, CETP, LCAT GAA 247/4885TDP1 2540/4885CNR1 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback